Compare Citius Pharmaceuticals Inc (CTXR) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Invesco S&P 500 High Div Low Volatility ETF trades at $51.98. The key difference: Invesco S&P 500 High Div Low Volatility ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | SPHD | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | — |
52-Week High | $1.82 | $52.63 |
52-Week Low | $0.53 | $46.96 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
SPHD trades at $52.18, up 0.69% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on high-dividend, low-volatility S&P 500 stocks, offering monthly income with a current yield around 4.5%. Recent news highlights its appeal to retirees seeking reliable income, though its long-term performance has lagged the broader market.
Outlook: SPHD provides defensive income but faces growth limitations. Opportunities include steady dividends and lower volatility; risks involve underperformance versus growth ETFs and sensitivity to interest rate changes. Investors should weigh income needs against total return expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
